πŸ‡ΊπŸ‡Έ FDA
Patent

US 9956293

Targeted therapeutics

granted A61KA61K31/167A61K31/337

Quick answer

US patent 9956293 (Targeted therapeutics) held by Madrigal Pharmaceuticals, Inc. expires Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Madrigal Pharmaceuticals, Inc.
Grant date
Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/167, A61K31/337, A61K31/357, A61K31/4184